Stručni rad
https://doi.org/10.20471/acc.2024.63.s2.11
Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-Making
Antonela Njavro
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Jure Murgić
orcid.org/0000-0001-8152-0494
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
*
Blanka Jakšić
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Marin Prpić
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia
Angela Prgomet Sečan
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Dora Franceschi
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Marija Miletić
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Slaven Ovčariček
; Department of Urology, Clinical Hospital Sveti Duh, Zagreb, Croatia
Adelina Hrkač
; Department of Urology, Clinical Hospital Sveti Duh, Zagreb, Croatia
Ivan Šamija
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; Department of Immunology, School of Dental Medicine, University of Zagreb, Zagreb, Croatia
Monika Ulamec
; Department of Pathology and Cytology “Ljudevit Jurak”, University Hospital Center Sestre milosrdnice, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia
Marijana Jazvić
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Pero Bokarica
; Department of Urology, Clinical Hospital Sveti Duh, Zagreb, Croatia
Igor Tomašković
; Department of Urology, University Hospital Center Sestre milosrdnice, Zagreb, Croatia; School of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia
Ana Fröbe
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia
* Dopisni autor.
Sažetak
Therapy decision-making in prostate cancer has traditionally been limited to clinical,
histopathological, and radiological variables that does not take into account the varying biology of prostate
cancer manifestations. It is well-known that disease stratification tools we use in our clinics every day
to customize therapy choices for individual patients with prostate cancer fail to capture and address the
wide ranges of observed disease clinical courses. Prostate cancer is characterized by significant intra- and
interpatient heterogeneity that makes this disease unique and extremely variable. The advent of affordable
next-generation genomic sequencing techniques has allowed the incorporation of these data into clinical
research, with enormous potential to aid clinical care in the future. The optimal goal of prostate cancer
treatment is to personalize treatment specific to a patient’s unique clinic-genomic phenotypes. We may
thus potentially avoid overtreatment in patients harboring less aggressive disease and undertreatment in
patients harboring more aggressive disease. Currently, we lack that ability if we rely only on clinical stratification
tools such as the NCCN model, CAPRA scoring, and D’Amico classification. It may be the
case that prostate cancer genomics hold the key to understanding and predicting the response to crucial
treatment modalities in prostate cancer: androgen deprivation therapy, radiotherapy, and next-generation
androgen pathway inhibition therapy. Currently, there are many open questions about how to use these
therapies optimally in individual patients. In this freeform narrative review, we summarize the literature
and current clinical practice of biomarkers in prostate cancer, specifically focusing on genomic tests utilized
in radiotherapy management and/or adjunctive therapies given with radiotherapy.
Ključne riječi
Biomarkers; Prostate cancer; Risk stratification; Genomics; Radiotherapy; Androgen deprivation therapy
Hrčak ID:
323260
URI
Datum izdavanja:
30.4.2024.
Posjeta: 0 *